The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 428,677 share decrease in total short interest for Proto Labs Inc (PRLB), to 3,815,495, a decrease of 10.10% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for PRLB at the 10/31/2017 settlement increased to 156,945, as compared to 122,743 at the 10/13/2017 report. That brought "days to cover" down to 24.31, a 29.69% decrease from the 34.58 days to cover calculated at the previous short interest data release.The below chart shows the historical "days to cover" for PRLB at previous short interest release dates: A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where PRLB had been shorted as a hedge. The chart below shows the one year performance of PRLB shares, versus its 200 day moving average. Looking at this chart, PRLB's low point in its 52 week range is $44.35 per share, with $89.95 as the 52 week high point — that compares with a last trade of $84.45. According to the ETF Finder at ETF Channel, PRLB makes up 3.31% of the First Trust RBA American Industrial Renaissance ETF (AIRR) which is lower by about 0.3% on the day Friday.
More from Stocks
Ellevest CEO Sallie Krawcheck Has a Message for Wall Street
Sallie Krawcheck sits down with TheStreet to discuss the investing gap, the pay gap and her thoughts on diversity.
Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround
Teva's CEO explains why 2019 is a trough year for the Israeli pharma company.
Investing Is a 'Constant Learning Game' According to M1 Finance CEO
The CEO M1 Finance says that investing means that you're constantly learning. Here's why.